Thermodynamic criterion for the conformation of P1 residues of substrates and of inhibitors in complexes with serine proteinases

被引:20
|
作者
Qasim, MA
Lu, SM
Ding, JH
Bateman, KS
James, MNG
Anderson, S
Song, JK
Markley, JL
Ganz, PJ
Saunders, CW
Laskowski, M [1 ]
机构
[1] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA
[2] Univ Alberta, Dept Biochem, MRC Canada, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada
[3] Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA
[4] Procter & Gamble Co, Miami Valley Labs, Cincinnati, OH 45253 USA
[5] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA
关键词
D O I
10.1021/bi990265u
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Eglin c, turkey ovomucoid third domain, and bovine pancreatic trypsin inhibitor (Kunitz) are all standard mechanism, canonical protein inhibitors of serine proteinases. Each of the three belongs to a different inhibitor family. Therefore, all three have the same canonical conformation in their combining loops but differ in their scaffoldings. Eglin c (Leu(45) at P-1) binds to chymotrypsin much better than its Ala(45) variant (the difference in standard free energy changes on binding is -5.00 kcal/mol). Similarly, turkey ovomucoid third domain (Leu(18) at P-1) binds to chymotrypsin much better than its Ala's variant (the difference in standard free energy changes on binding is -4.70 kcal/mol). As these two differences are within the +/-400 cal/mol bandwidth (expected from the experimental error), one can conclude that the system is additive. On the basis that isoenergetic is isostructural, we expect that within both the P-1 Ala pair and the P-1 Leu pair, the conformation of the inhibitor's P-1 side chain and of the enzyme's specificity pocket will be identical. This is confirmed, within the experimental error, by the available X-ray structures of complexes of bovine chymotrypsin A alpha with eglin c (lacb) and with turkey ovomucoid third domain (1cho). A comparison can also be made between the structures of P-1 (Lys(+))(15) of bovine pancreatic trypsin inhibitor (Kunitz) (1mtn and 1cbw) and of the P-1 (Lys(+))(18) variant of turkey ovomucoid third domain (1hja), both interacting with chymotrypsin. In this case, the conformation of the side chains is strikingly different. Bovine pancreatic trypsin inhibitor with (Lys(+))(15) at P-1 binds to chymotrypsin more strongly than its Ala(15) variant (the difference in standard free energy changes on binding is -1.90 kcal/mol). In contrast, turkey ovomucoid third domain variant with (Lys(+))(18) at P-1 binds to chymotrypsin less strongly than its Ala(18) variant (the difference in standard free energies of association is 0.95 kcal/mol). In this case, P-1 Lys(+) is neither isostructural nor isoenergetic. Thus, a thermodynamic criterion for whether the conformation of a P-1 side chain in the complex matches that of an already determined one is at hand. Such a criterion may be useful in reducing the number of required X-ray crystallographic structure determinations. More importantly, the criterion can be applied to situations where direct determination of the structure is extremely difficult. Here, we apply it to determine the conformation of the Lys(+) side chain in the transition state complex of a substrate with chymotrypsin. On. the basis of k(cat)/K-M measurements, the difference in free energies of activation for Suc-AAPX-pna when X is Lys(+) and X is Ala is 1.29 kcal/mol. This is in good agreement with the corresponding difference for turkey ovomucoid third domain variants but in sharp contrast to the bovine pancreatic trypsin inhibitor (Kunitz) data. Therefore, we expect that in the transition state complex of this substrate with chymotrypsin, the P-1 Lys(+) side chain is deeply inserted into the enzyme's specificity pocket as it is in the (Lys(+))(18) turkey ovomucoid third domain complex with chymotrypsin.
引用
收藏
页码:7142 / 7150
页数:9
相关论文
共 50 条
  • [21] The synthesis of symmetrical and unsymmetrical P1/P1′ cyclic ureas as HIV protease inhibitors
    Patel, M
    Kaltenbach, RF
    Nugiel, DA
    McHugh, RJ
    Jadhav, PK
    Bacheler, LT
    Cordova, BC
    Klabe, RM
    Erickson-Viitanen, S
    Garber, S
    Reid, C
    Seitz, SP
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (09) : 1077 - 1082
  • [22] MATRIX METALLOPROTEINASE INHIBITORS CONTAINING A (CARBOXYALKYL)AMINO ZINC LIGAND - MODIFICATION OF THE P1 AND P2' RESIDUES
    BROWN, FK
    BROWN, PJ
    BICKETT, DM
    CHAMBERS, CL
    DAVIES, HG
    DEATON, DN
    DREWRY, D
    FOLEY, M
    MCELROY, AB
    GREGSON, M
    MCGEEHAN, GM
    MYERS, PL
    NORTON, D
    SALOVICH, JM
    SCHOENEN, FJ
    WARD, P
    JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (05) : 674 - 688
  • [23] Stoichiometry of P1 plasmid partition complexes
    Bouet, JY
    Surtees, JA
    Funnell, BE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (11) : 8213 - 8219
  • [24] Substrates with charged P-1 residues are efficiently hydrolyzed by serine carboxypeptidases when S-3-P-1 interactions are facilitated
    Olesen, K
    Breddam, K
    BIOCHEMISTRY, 1997, 36 (40) : 12235 - 12241
  • [25] α-Keto Phenylamides as P1′-Extended Proteasome Inhibitors
    Voss, Constantin
    Scholz, Christoph
    Knorr, Sabine
    Beck, Philipp
    Stein, Martin L.
    Zall, Andrea
    Kuckelkorn, Ulrike
    Kloetzel, Peter-Michael
    Groll, Michael
    Hamacher, Kay
    Schmidt, Boris
    CHEMMEDCHEM, 2014, 9 (11) : 2557 - 2564
  • [26] Potent P1′ biphenylmethyl substituted aggrecanase inhibitors
    Yao, WQ
    Chao, M
    Wasserman, ZR
    Liu, RQ
    Covington, MB
    Newton, R
    Christ, D
    Wexler, RR
    Decicco, CP
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (01) : 101 - 104
  • [27] Noncovalent thrombin inhibitors incorporating an imidazolylethynyl P1
    Lee, K
    Jung, WH
    Kang, M
    Lee, SH
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (24) : 2775 - 2778
  • [28] Increased antiviral activity of cyclic urea HIV protease inhibitors by modifying the P1/P1′ substituents
    Kaltenbach, RF
    Klabe, RM
    Cordova, BC
    Seitz, SP
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (15) : 2259 - 2262
  • [29] Design, synthesis and SAR of potent statin-based β-secretase inhibitors: Exploration of P1 phenoxy and benzyloxy residues
    Back, Marcus
    Nyhlen, Jonas
    Kvarnstrom, Ingemar
    Rosenquist, Asa
    Samuelsson, Berta
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
  • [30] A novel endopeptidase with a strict specificity for threonine residues at the P1′ position
    Niamké, S
    Sine, JP
    Guionie, O
    Colas, B
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 256 (02) : 307 - 312